Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry

Direct Health Care Costs Associated with Asthma in British Columbia

(2016) Mohsen Sadatsafavi et al.   Canadian Respiratory Journal

Omalizumab for severe allergic asthma in clinical trials and real-life studies: What we know and what we should address

(2015) Marco Caminati et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Exploring the Effects of Omalizumab in Allergic Asthma

(2013) Nicola A. Hanania et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

(2013) K. F. Chung et al.   EUROPEAN RESPIRATORY JOURNAL

Profile of patients treated with omalizumab in routine clinical practice in Spain

(2012) J. Ancochea et al.   ALLERGOLOGIA ET IMMUNOPATHOLOGIA

Exacerbations of severe asthma

(2012) V. M. McDonald et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Asthma phenotypes: the evolution from clinical to molecular approaches

(2012) Sally E Wenzel   NATURE MEDICINE

Omalizumab in patients with severe asthma: the XCLUSIVE study

(2011) Christian Schumann et al.   Clinical Respiratory Journal

Controlled and uncontrolled allergic asthma in routine respiratory specialist care – a clinical–epidemiological study in Germany

(2011) P. Kardos et al.   CURRENT MEDICAL RESEARCH AND OPINION

Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI)

(2010) E. H. Bel et al.   THORAX

Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry

(2010) L. G. Heaney et al.   THORAX